Loading...
Starpharma Holdings Limited
SPL.AX•ASX
Healthcare
Biotechnology
A$0.10
A$-0.00(-4.00%)
Starpharma Holdings Limited (SPL.AX) Financial Performance & Income Statement Overview
Review Starpharma Holdings Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
182.03%
↑ 182.03%
Operating Income Growth
38.56%
↑ 38.56%
Net Income Growth
47.79%
↑ 47.79%
Operating Cash Flow Growth
48.44%
↑ 48.44%
Operating Margin
-626.79%
↓ 626.79%
Gross Margin
-138.24%
↓ 138.24%
Net Profit Margin
-301.18%
↓ 301.18%
ROE
-48.83%
↓ 48.83%
ROIC
-105.23%
↓ 105.23%
Starpharma Holdings Limited (SPL.AX) Income Statement & Financial Overview
Review Starpharma Holdings Limited's (SPL.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $1.73M | $7.20M | $1.85M | $1.09M |
| Cost of Revenue | $5.22M | $770000.00 | $868000.00 | $1.16M |
| Gross Profit | -$3.49M | $6.43M | $985000.00 | -$69000.00 |
| Gross Profit Ratio | -$2.02 | $0.89 | $0.53 | -$0.06 |
| R&D Expenses | $7.23M | $8.35M | $8.96M | $9.90M |
| SG&A Expenses | $3.64M | $3.03M | $3.48M | $3.23M |
| Operating Expenses | $10.87M | $11.38M | $12.45M | $13.14M |
| Total Costs & Expenses | $16.09M | $12.15M | $13.32M | $14.29M |
| Interest Income | $639000.00 | $828000.00 | $748000.00 | $521000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $546000.00 | $569000.00 | $580000.00 | $613000.00 |
| EBITDA | -$6.98M | -$3.56M | -$10.11M | -$11.97M |
| EBITDA Ratio | -$4.03 | -$0.61 | -$5.87 | -$11.60 |
| Operating Income | -$14.36M | -$4.95M | -$11.46M | -$13.21M |
| Operating Income Ratio | -$8.29 | -$0.69 | -$6.19 | -$12.16 |
| Other Income/Expenses (Net) | $4.79M | $828000.00 | $779000.00 | $625000.00 |
| Income Before Tax | -$9.57M | -$4.13M | -$10.69M | -$12.58M |
| Income Before Tax Ratio | -$5.53 | -$0.57 | -$5.77 | -$11.59 |
| Income Tax Expense | -$2.44M | -$3.09M | -$3.33M | -$4.31M |
| Net Income | -$7.13M | -$1.03M | -$7.36M | -$8.28M |
| Net Income Ratio | -$4.12 | -$0.14 | -$3.97 | -$7.62 |
| EPS | -$0.02 | -$0.003 | -$0.02 | -$0.02 |
| Diluted EPS | -$0.02 | -$0.003 | -$0.02 | -$0.02 |
| Weighted Avg Shares Outstanding | $407.98M | $410.86M | $409.54M | $408.59M |
| Weighted Avg Shares Outstanding (Diluted) | $412.37M | $410.86M | $409.54M | $408.59M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan